帕利哌酮联合中成药治疗脑外伤所致精神障碍36例

摘要

目的：探讨帕利哌酮联合中成药治疗脑外伤所致精神障碍的临床疗效及安全性。方法将72例脑外伤致精神障碍患者随机分为对照组和观察组，各36例。对照组给予帕利哌酮缓释片治疗，观察组在对照组基础上加用黄芪注射液和血府逐瘀胶囊。于治疗前及治疗后2，4，6，8周末采用阳性与阴性症状量表（PANSS）进行评分，观察临床疗效，监测帕利哌酮的起效时间、用药剂量，记录不良反应。结果治疗8周后，观察组总有效率为97.22%，明显高于对照组的86.11%（ P <0.05）；观察组 PANSS 总分及各因子分与对照组相比均有显著下降（ P <0.05），观察组平均起效时间短于对照组，帕利哌酮日平均剂量少于对照组，不良反应发生率低于对照组，差异均有统计学意义（ P <0.05）。结论帕利哌酮联合中成药治疗脑外伤后伴躁狂的精神障碍，疗效确切，起效更快，控制症状更迅速，用药剂量少，不良反应少，值得临床推广。%Objective To explore the clinical efficacy and safety of paliperidone combined with Chinese patent drug in treating mental dis-orders caused by brain trauma. Methods 72 patients with mental disorders caused by brain trauma were randomly divided into the control group and the treatment group,36 cases in each group. The control group was given Paliperidone Sustained Release Tablet,while on this basis the observation group was added with Huangqi Injection and Xuefuzhuyu Capsule. The clinical efficacy was assessed before treatment and at 2,4,6,8 weeks after treatment with the Positive and Negative Syndrome Scale(PANSS). The adverse reactions were evaluated with the Treatment Emergent Symptoms Scale(TESS). The clinical effects were observed and compared between the two groups. The effect onset time,dosage,adverse reactions were recorded. Results The total effective rates after 8 - week treatment were 97. 22% in the observation group and which is significantly higher than 86. 11% in the control group( P < 0. 05);the total and each factor scores of PANSS in the observation group were significantly decreased compared with the control group( P < 0. 05). The average effect onset time in the observa-tion group was shorter than that in the control group,the average dosage of paliperidone was less than that in the control group,and the occurrence rate of adverse reactions was lower than that in the control group,the differences had statistical significance( P < 0. 05). Conclusion Paliperidone combined with Chinese patent drug for treating mental disorders caused by brain trauma has definite effect,rapid onset,rapid control of symptoms,small dose and less adverse reactions,which is worthy of clinical promotion.